Treatment of congenital heart disease associated pulmonary hypertension

先天性心脏病相关肺动脉高压的治疗

基本信息

  • 批准号:
    8831801
  • 负责人:
  • 金额:
    $ 150万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-01 至 2017-03-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Restoration of the balance of the free radicals nitric oxide (NO) and superoxide in the pulmonary vasculature may prevent life-threatening perioperative pulmonary hypertension (PH) in children with congenital heart defects (CHD) undergoing surgical correction of a left-to-right shunt. In rodent models of PH, intratracheal (IT) administration of R-190, a bifunctional NO donor and redox catalyst prodrug intended to correct free radical imbalance, selectively and profoundly reduces mean pulmonary arterial pressure (MPAP) without impacting systemic mean arterial pressure (MAP) or heart rate (HR). R-100, the metabolite of R-190, inhibits vascular remodeling. R-190 is dephosphorylated in vivo to form an intermediate, R-188, which is then hydrolyzed to form para-hydroxyphenylacetate (PHPA) and 3- nitratoproxyl-hydroxylamine. The freed PHPA detoxifies peroxynitrite, the reaction product of NO with superoxide anion, while the liberated 3-nitratoproxyl-hydroxylamine oxidizes to form R-100, a molecule serving as: a) a nitric oxide donor via its organic nitrate, and b) a broad-spectrum catalyst of reactive oxygen species degradation via its nitroxide moiety. The fusion of all the above functional domains into a single entity (R-190) assures that their multiple biologica activities are co-localized. The unique potency, selectivity, and sustained duration of effect justify development of R-190 for perioperative prevention of PH in CHD. Aim #1: Establish the pharmacodynamic (PD) profile of R-190 in a lamb model of PH induced by a thromboxane mimetic Juvenile lambs will undergo continuous infusion with the pulmonary-selective vasoconstrictor U-46619 to achieve a MPAP = 25-30 mmHg. R-190 (0, 1, 3, 10, 30 mg/kg nebulized per IT) will be compared to inhaled NO (iNO) for the amplitude and duration of its effect on SVR and PVR. Blood will be collected for correlation of PVR and SVR with the plasma concentrations of R-190 and its major metabolites. Aim #2: Determine the efficacy of R-190 in a lamb model of perioperative pulmonary hypertension induced by cardiopulmonary bypass (CPB) and surgical correction of a congenital left-t0- right shunt Juvenile lambs with PH (MPAP = ~25 mmHg) induced by in utero placement of a pulmonary - aortic window will undergo CPB and surgical closure of the arteriovenous connection. Directly following CPB, the effect of a single dose of nebulized IT R-190 or vehicle control will be compared to iNO (40 ppm) for the amplitude and duration of its effect on SVR and PVR. Aim #3: Establish the acute safety, stability, and tolerance of the aerosolized R-190 by IND-enabling toxicology and safety pharmacology studies. Lovelace Biomedical and Environmental Research Institute will carry out GLP-grade in vivo dose range- finding and 14 day repeat-dose toxicology investigations in juvenile rats and dogs, with a 14-day recovery period. RTX will then prepare and submit a full IND application to the FDA for a Phase 1a clinical dose- escalation study.
 描述(由申请人提供):恢复肺血管内自由基一氧化氮(NO)和超氧化物歧化酶(O2)的平衡,可以预防先天性心脏病(CHD)患儿在接受左向右分流手术矫正时发生危及生命的围手术期肺动脉高压(PH)。在PH的啮齿动物模型中,气管内(IT) R-190是一种用于纠正自由基失衡的双功能一氧化氮供体和氧化还原催化剂前体药物,使用R-190可以选择性而深刻地降低平均肺动脉压(MPAP),而不影响全身平均动脉压(MAP)或心率(HR)。R-100是R-190的代谢产物,可抑制血管重塑。R-190在体内被脱磷,形成中间体R-188,然后被水解形成对羟基苯乙酸酯(PHPA)和3-硝基-羟胺。释放的PHPA解毒过氧亚硝酸盐,过氧亚硝酸盐是NO与超氧阴离子反应的产物,而释放的3-硝酸羟胺氧化形成R-100,R-100分子是:a)通过其有机硝酸盐作为一氧化氮供体,b)通过其氮氧化物部分降解活性氧物种的广谱催化剂。所有上述功能结构域的融合成一个单一实体(R-190)确保了它们的多种生物学活性是共定位的。R-190的独特效力、选择性和持续时间为开发R-190预防冠心病围手术期PH提供了依据。目的#1:在拟血栓素诱导的羔羊PH模型中建立R-190的药效学(PD)模型。幼年羔羊将接受肺选择性血管收缩药U-46619的持续输注,以达到25-30毫米汞柱的最大呼气压力。将R-190(每IT雾化0、1、3、10、30 mg/kg)与吸入NO(INO)进行比较,以观察其对SVR和PVR作用的幅度和持续时间。将采集血液进行PVR和SVR与血浆R-190及其主要代谢物浓度的相关性研究。目的#2:探讨R-190对体外循环(CPB)围术期肺动脉高压和先天性左、右分流性肺动脉高压(MPAP=~25 mm Hg)的疗效。CPB结束后,单次雾化吸入IT R-190或车辆控制剂的效果将与iNO(40ppm)在SVR和PVR上的作用幅度和持续时间进行比较。目的#3:通过IND毒理学和安全药理学研究,确定雾化R-190的急性安全性、稳定性和耐受性。Lovelace生物医学和环境研究所将在幼年大鼠和狗身上进行GLP级体内剂量范围发现和14天重复剂量毒理学研究,恢复期为14天。然后,RTX将准备一份完整的IND申请,并提交给FDA进行1a期临床剂量递增研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW Lurie SALZMAN其他文献

ANDREW Lurie SALZMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW Lurie SALZMAN', 18)}}的其他基金

A Novel Immunotolerizing Therapy for Autoimmune Vitiligo
一种治疗自身免疫性白癜风的新型免疫耐受疗法
  • 批准号:
    8713488
  • 财政年份:
    2014
  • 资助金额:
    $ 150万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9342949
  • 财政年份:
    2012
  • 资助金额:
    $ 150万
  • 项目类别:
Resuscitation of smoke inhalation and burn injury with a thioredoxin mimetic
用硫氧还蛋白模拟物复苏烟雾吸入和烧伤
  • 批准号:
    8338756
  • 财政年份:
    2012
  • 资助金额:
    $ 150万
  • 项目类别:
A Redox-active PARP Inhibitor for Lung Transplantation
用于肺移植的氧化还原活性 PARP 抑制剂
  • 批准号:
    8391286
  • 财政年份:
    2012
  • 资助金额:
    $ 150万
  • 项目类别:
Restoration of free radical homeostasis: novel therapy of septic shock
恢复自由基稳态:感染性休克的新疗法
  • 批准号:
    9140177
  • 财政年份:
    2012
  • 资助金额:
    $ 150万
  • 项目类别:
Bifunctional Redox Catalyst & Organic Nitrate for Limb Reperfusion
双功能氧化还原催化剂
  • 批准号:
    8522327
  • 财政年份:
    2011
  • 资助金额:
    $ 150万
  • 项目类别:
PARP inhibition for thoraco-abdominal aneurysm surgery
PARP 抑制在胸腹动脉瘤手术中的应用
  • 批准号:
    6933563
  • 财政年份:
    2005
  • 资助金额:
    $ 150万
  • 项目类别:
PARP inhibitory therapy of acute ischemic stroke
PARP抑制治疗急性缺血性脑卒中
  • 批准号:
    6785744
  • 财政年份:
    2004
  • 资助金额:
    $ 150万
  • 项目类别:
PARP inhibitor therapy for septic shock
PARP 抑制剂治疗感染性休克
  • 批准号:
    6790412
  • 财政年份:
    2004
  • 资助金额:
    $ 150万
  • 项目类别:
Inosine pro-drug: novel therapy for arthritis
肌苷前药:关节炎的新疗法
  • 批准号:
    6867616
  • 财政年份:
    2003
  • 资助金额:
    $ 150万
  • 项目类别:

相似海外基金

Exploring the mental health and wellbeing of adolescent parent families affected by HIV in South Africa
探讨南非受艾滋病毒影响的青少年父母家庭的心理健康和福祉
  • 批准号:
    ES/Y00860X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
    Fellowship
Scaling-up co-designed adolescent mental health interventions
扩大共同设计的青少年心理健康干预措施
  • 批准号:
    MR/Y020286/1
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
    Fellowship
Shared Spaces: The How, When, and Why of Adolescent Intergroup Interactions
共享空间:青少年群体间互动的方式、时间和原因
  • 批准号:
    ES/T014709/2
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
    Research Grant
Social Media Mechanisms Affecting Adolescent Mental Health (SoMe3)
影响青少年心理健康的社交媒体机制 (SoMe3)
  • 批准号:
    MR/X034925/1
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
    Fellowship
Parent-adolescent informant discrepancies: Predicting suicide risk and treatment outcomes
父母与青少年信息差异:预测自杀风险和治疗结果
  • 批准号:
    10751263
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
Adolescent sugar overconsumption programs food choices via altered dopamine signalling
青少年糖过度消费通过改变多巴胺信号来影响食物选择
  • 批准号:
    BB/Y006496/1
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
    Research Grant
The Impact of Online Social Interactions on Adolescent Cognition
在线社交互动对青少年认知的影响
  • 批准号:
    DE240101039
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
    Discovery Early Career Researcher Award
Resilience Factors, Pain, and Physical Activity in Adolescent Chronic Musculoskeletal Pain
青少年慢性肌肉骨骼疼痛的弹性因素、疼痛和体力活动
  • 批准号:
    10984668
  • 财政年份:
    2024
  • 资助金额:
    $ 150万
  • 项目类别:
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 150万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Evaluating the impact of changes in the proximity and density of vape retailers around secondary schools in Ontario on adolescent vaping behaviours
评估安大略省中学周围电子烟零售商的距离和密度变化对青少年电子烟行为的影响
  • 批准号:
    500515
  • 财政年份:
    2023
  • 资助金额:
    $ 150万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了